This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0861

Assessment of cognitive impairment in Bangladeshi patients with Parkinson’s disease in Dhaka

ASSESSMENT OF COGNITION IMPAIRMENT IN PARKINSON'S DISEASE IN BANGLADESHI PATIENT IN DHAKA

The rate of cognitive impairment is significantly higher in Bangladeshi patients with Parkinson’s disease than in healthy controls (86.1% versus 46.3% according to the MoCA, p<0.001).

The study aimed to determine the prevalence of cognitive impairment (CI) in Bangladeshi people with Parkinson’s disease (PwP) and to compare the cultural appropriateness of standard cognitive scales with newer alternatives. In this case-control study, conducted at the movement disorders clinic of Bangladesh Medical University in Dhaka between December 2022 and January 2025, 199 patients with Parkinson’s disease and 101 healthy controls (HC), comprising patients’ spouses and university staff, were assessed. Motor (UPDRS, Hoehn and Yahr), non-motor (NMSQuest, HADS), and cognitive (MoCA, CDR, RUDAS) assessments and computer-based cognitive tests were administered, and blood samples were collected. Age at assessment was 59.9±10.5 years in the patient group and 53.3±10.3 years in controls, a significant difference (p<0.001); age at symptom onset was 55.8±10.6 years, age at diagnosis was 56.2±10.7 years, and time since diagnosis was 3.6±3.9 years. Among comorbidities, hypertension was present in 43.9% of patients and 23.2% of controls (p=0.001), while there were no differences in type 2 diabetes (p=0.92) or smoking (p=0.44); RBDSQ scores were 3.8±2.3 and 1.2±1.2, respectively (p<0.001). Among the 137 patients and 82 controls whose cognitive scale scores were compared, MoCA scores were 16.3±7.6 versus 24.0±5.4, CDR scores were 0.6±0.5 versus 0.1±0.2, and RUDAS scores were 20.5±6.2 versus 25.7±4.9, all with p<0.001. Using a MoCA cut-off of 25/30 or below, 86.1% of patients and 46.3% of controls scored within the range indicating cognitive impairment (p<0.001). In patients, the median LEDD was reported as 300±200, UPDRS III as 28.4±16.0, total UPDRS as 34.1±7.5, HADS depression as 8.3±2.7, and HADS anxiety as 6.8±2.5. The authors state that this first large-scale study of Parkinson’s disease in Bangladesh indicates early onset, a high burden of non-motor symptoms and vascular comorbidities, and marked cognitive impairment, highlighting the need for culturally adapted assessment tools, integrated care, and longitudinal follow-up.

All WCP 2026 summaries